Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Inclusion Criteria

• •The diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy revealing refractory anemia, or primary refractory leukopenia or thrombocytopenia with morphologic features of MDS; patients with 5q- syndrome are ineligible; patients with RA and RARS are eligible provided they are transfusion dependent. Patients with chronic myelomonocytic leukemia (CMMoL) are eligible; allogeneic BMT will be the treatment priority for patients with HLA-matched siblings; MDS patients for whom intensive chemotherapy has failed to achieve remission will be candidates for this trial if the chemotherapy was administered \> 1 month prior to enrollment, and performance status is adequate; patients are also eligible having previously progressed on other institutional trials, including phenylbutyrate and ATRA or 5'-azacytadine
• •Patients must have a bone marrow aspirate or biopsy confirmed diagnosis of relapsed AML within 4 weeks of registering for this trial; patients will be eligible only if their WBC is \< 30 x 103/:l and stable for at least 7 days, and if they are unlikely to require cytotoxic therapy during the duration of the trial; patients may not have APL
• •All patients with PNH will be eligible provided they are experiencing symptoms associated with their disease; in particular, patients experiencing life-threatening complications of their illness, including abdominal, central vein or cerebral thromboses, active infections, as well as recurrent, symptomatic hemolytic crises and do not have other treatment options are encouraged to consider participation
• •JHOC confirmed and documented diagnosis of either AML, MDS, CML in accelerated or blast phase or PNH
• •Patients must have relatively stable bone marrow function for more than ten days prior to enrollment on the study; WBC count doubling within this time period would indicate unstable bone marrow function
• •ECOG performance status of 0, 1, 2
• •Patients must have central intravenous access; acceptable access include: PICC lines, hickman and hohn catheters, and port-a-caths
• •Patient or caregiver must be willing to perform subcutaneous injection
• •Serum creatinine \< 2.0 mg/dL
• •Total serum bilirubin =\< 1.6 mg/dL, unless secondary to hemolysis
• •SGOT/SGPT each \< 2 times the upper limit of normal unless disease related (i.e., PNH, extramedullary disease)
• •Hemoglobin should be at least 8 gm/dL at the time of protocol entry; patients may receive transfusions to achieve this level
• •Patients must not have received treatment for their myeloid disorder within 2 weeks of beginning the trial; treatments include the use of chemotherapy, hematopoietic growth factors, and biologic therapy such as monoclonal antibodies; the exception is the use of hydroxyurea for patients with WBC \> 10 x 103/:L; this duration of time appears adequate for wash out due to the relatively short-acting nature of most anti-leukemia agents
• •Patients must have recovered from all toxicities (to grade 0 or 1) associated with previous treatment
• •Patients must not have any clinical symptoms of active CNS disease; if CNS disease is suspected, patient must have LP with negative cytology
• •Patients must not have evidence of pulmonary leukostasis (i.e., the clinical syndrome associated with symptomatic shortness of breath or hypoxia which is directly attributed to an elevated white blood cell count and the resulting capillary ischemia) or disseminated intravascular coagulation (i.e., the clinical syndrome associated with systemic intravascular clotting which is directly attributed to excessive procoagulants that overwhelm the inhibitory arm of the coagulation cascade)
• •All women of potential child bearing must have negative serum B-HCG and use an effective means of birth control throughout the trial period
• •Patients must be able to provide informed consent and to return to clinic for adequate follow up as required by the protocol